Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.31 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14296411 | 0.95 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL16675113 | 0.95 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL14338482 | 0.95 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL14644931 | 0.94 | CA2 (0.40) | CA2PYGBOGASLC6A2GAA | |
| SCHEMBL14197413 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL22130784 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL12834727 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL12761989 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL14185961 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 | |
| SCHEMBL13292758 | 0.93 | CA2 (0.35) | CA2PYGBOGASLC6A2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072782-B2 | Gadolinium complex, method for preparing same, and MRI contrast agent comprising same | CATHLOIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2015-07-07 | — | — | US | disclosed |
| US-20120058054-A1 | GADOLINIUM COMPLEX, METHOD FOR PREPARING SAME, AND MRI CONTRAST AGENT COMPRISING SAME | Catholic University Industry Academic Cooperation Foundation (KR) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058054-A1 | GADOLINIUM COMPLEX, METHOD FOR PREPARING SAME, AND MRI CONTRAST AGENT COMPRISING SAME | GMNN, FABP1, GOT1 | CA2 1913/4885PYGB 865/4885OGA 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.